Results 91 to 100 of about 2,052,688 (283)

Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor

, 2013
Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric ...
CSM Yong (14473233), MA Henderson (14480322), P Neeson (13533949), PK Darcy (14473242), JA Westwood (14473230), MH Kershaw (14473245), CPM Duong (15789299), AJ Davenport (15450752), Liza John (18763624), C Devaud (13423683)   +9 more
core  

Optimizing tumor-targeting chimeric antigen receptor T cells in B-cell lymphoma patients

, 2011
Evaluation of: Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121(5), 1822–1826 (2011). Chimeric antigen receptor (CAR)-T cells
Kimberley Jones, Maher Gandhi
core   +1 more source

Supplementary Table from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors

, 2022
Supplementary Table from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid ...
Jessica Hong (15090075), Markku Miettinen (15049911), Mitchell Ho (15090090), Jingli Zhang (15090069), Sakshi Tomar (15090066), Manakamana Khanal (15090072), Ira Pastan (15085516), Qun Jiang (15090081), Manjistha Sengupta (15090084), Raffit Hassan (15090093), Abhilash Venugopalan (15090078), Nan Li (15090087)   +11 more
core   +1 more source

TROP2‐Targeting Chimeras (TRTACs) for Tumor Cell‐Selective Membrane Protein Degradation and Enhanced Drug Delivery

Advanced Science, EarlyView.
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen, Xinying Fu, Wenqian Dong, Xiaobei Deng, Simin Chen, Fujun Wang, Jian Zhao, Shiqun Shao, Liqiang Fan, Jingyu Zhang, Lixin Zhang   +10 more
wiley   +1 more source

Supplementary Figure from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors

, 2022
Supplementary Figure from Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid ...
Jessica Hong (15090075), Markku Miettinen (15049911), Mitchell Ho (15090090), Jingli Zhang (15090069), Sakshi Tomar (15090066), Manakamana Khanal (15090072), Ira Pastan (15085516), Qun Jiang (15090081), Manjistha Sengupta (15090084), Raffit Hassan (15090093), Abhilash Venugopalan (15090078), Nan Li (15090087)   +11 more
core   +1 more source

ERα–PADI4–CXCL8 Axis Drives MDSC‐Mediated Immune Evasion in Anaplastic Thyroid Carcinoma

Advanced Science, EarlyView.
MAPK‐driven ligand‐independent ERα activation drives PADI4 transcription and translation. This enzyme then modifies CXCL8 chemokines through citrullination, generating a potent chemoattractant gradient specifically for myeloid‐derived suppressor cells.
Dongdong Zhang, Ying Cai, Junbin Zhang, Jianyong Zhang, Ran Jing, Ming Cai   +5 more
wiley   +1 more source

Genetic modification of mouse effector and helper T lymphocytes expressing a chimeric antigen receptor.

, 2014
Genetic modification of mouse effector and helper T lymphocytes expressing a chimeric antigen ...
P Darcy (18763603), D Gilham (18763600), Tess Chee (13027890), Liza Raymond (13082100)   +3 more
core  

SPRED2 Negatively Regulates CD8+ T Cell‐Mediated Antitumor Immunity in Breast Cancer

Advanced Science, EarlyView.
Sprouty‑related EVH1 domain containing 2 (SPRED2) restrains Ras/Raf/ERK signaling in CD8+ T cells. Host SPRED2 deficiency enhances T‐cell survival, cytotoxicity, and memory‐like phenotypes, reducing primary tumor growth and endpoint lung metastatic burden in breast cancer models.
Miao Tian, Teizo Yoshimura, Kun Zhao, Chunning Li, Tong Gao, Ziyi Wang, Masayoshi Fujisawa, Toshiaki Ohara, Akihiro Matsukawa   +8 more
wiley   +1 more source

Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment

Frontiers in Immunology, 2017
Primary human natural killer (NK) cells recognize and subsequently eliminate virus infected cells, tumor cells, or other aberrant cells. However, cancer cells are able to develop tumor immune escape mechanisms to undermine this immune control.
Olaf Oberschmidt, Stephan Kloess, Ulrike Koehl   +2 more
doaj   +1 more source

Chimeric antigen receptor cell therapies: From anticancer immunity to tissue repair and neural regeneration

Originally developed as breakthroughs in cancer immunotherapy, Chimeric antigen receptor cell therapies have recently attracted attention because of their potential to promote tissue repair and functional restoration.
Aarchi A. Bharadia, Vibha G. Kanjani, Kashvy R. Morakhia   +2 more
core   +1 more source